Chinese (Simplified)
English
German
Korean
Spanish
Sign up for an account to enjoy easy online shopping and instant order tracking.
Single B cell antibody technology enables the direct isolation of antigen-specific B cells from immunized animals, followed by amplification and recovery of native antibody variable region sequences. Compared with traditional hybridoma methods, this approach shortens the discovery timeline and provides direct access to naturally paired heavy and light chain sequences without the need for cell fusion.
At AbTriva, our single B cell-based monoclonal antibody development service is designed for projects requiring high-affinity antibody discovery, difficult antigen targeting, or rapid sequence recovery workflows. This platform is particularly useful for antigens that are unstable in hybridoma screening or require precise epitope targeting.
We integrate antigen preparation, immunization, B cell isolation, single-cell screening, VH/VL amplification, recombinant expression, and functional validation into a streamlined discovery pipeline.
This platform is especially suitable for:
For standard screening-heavy workflows or large clone libraries, hybridoma-based approaches may still be preferred depending on project design.
Our single B cell antibody discovery workflow is built around rapid identification of antigen-specific B cells and direct antibody gene recovery.
| Step | Workflow Stage | Key Activities | Deliverable / Outcome |
|---|---|---|---|
| Step 1 | Antigen Preparation & Immunization |
|
Immunized animals with confirmed antibody response |
| Step 2 | B Cell Enrichment |
|
Enriched antigen-specific B cell population |
| Step 3 | Single B Cell Screening |
|
Antigen-specific single B cell clones |
| Step 4 | VH/VL Amplification & Sequencing |
|
Verified paired VH/VL antibody sequences |
| Step 5 | Recombinant Expression |
|
Purified recombinant monoclonal antibodies |
| Step 6 | Functional Validation |
|
Comprehensive functional validation data |
| Step 7 | High-Quality Antibody Ready for Use |
|
Ready-to-use recombinant monoclonal antibodies with complete project documentation |
Depending on project scope, typical deliverables include:
No hybridoma fusion step is required, reducing artifacts introduced by cell fusion instability.
Early sequence recovery enables earlier recombinant expression and optimization.
Improved likelihood of capturing rare high-affinity clones.
Sequences are immediately compatible with downstream engineering and production.
| Feature | Single B Cell | Hybridoma |
|---|---|---|
| Timeline | Faster | Longer |
| Sequence recovery | Direct | Indirect |
| Stability dependency | Low | Cell line dependent |
| Clone diversity | High | Moderate |
| Screening format | Single-cell | Colony-based |
Single B cell discovery is highly sensitive to immune response quality and sorting efficiency. The following factors may affect success rate:
We evaluate antigen design and immunization strategy prior to project initiation to determine feasibility and optimize expected outcomes.
Single B cell-derived monoclonal antibodies are widely used in:
We recommend early-stage discussion of:
Our scientific team will evaluate feasibility and propose a customized discovery strategy aligned with your research goals.
Accelerate your antibody discovery program with AbTriva's integrated single B cell platform.
Getting Started
Free shipping on orders $999+
Advenit post multos Scudilo Scutariorum tribunus velament
We accept credit cards, PayPal, and bank wires
Responsive and knowledgable customer service via email, text or phone
Notification
